摘要
Abstract
Objective To observe the clinical efficacy of apatinib combined with camrelizumab in the lat-er-line treatment of advanced colorectal cancer(CRC).Methods A total of 64 patients with advanced CRC were randomly divided into a control group and an observation group,with 32 cases in each group.Pa-tients in the control group were treated with apatinib,while patients in the observation group received apa-tinib combined with camrelizumab on the basis of the control group's treatment regimen.The efficacy,im-mune function,tumor markers,progression-free survival time(PFS),overall survival time(OS)and the occurrence of adverse reactions were compared between the two groups.Results The disease control rate of the observation group was higher than that of the control group(P＜0.05).There was no statisti-cally significant difference in immune function indicators between the two groups before treatment(P＞0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the observation group were higher than those in the control group(P＜0.05),while the level of CD8+was lower than that in the control group(P＜0.05).There was no statistically significant difference in levels of tumor markers between the two groups before treatment(P＞0.05).After treatment,the levels of carcinoembryonic antigen,carbo-hydrate antigen72-4(CA72-4)and carbohydrate antigen19-9(CA19-9)in the observation group were low-er than those in the control group(P＜0.05).After treatment,the PFS and OS of the observation group were longer than those of the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Apatinib combined with camrelizumab in the later-line treatment of advanced CRC has good efficacy.It can not only regulate the immune system and enhance immune function,but also reduce the levels of tumor markers and prolong the survival time of patients without increasing the incidence of adverse reactions.关键词
晚期结直肠癌/阿帕替尼/卡瑞利珠单抗/疗效观察Key words
Advanced colorectal cancer/Apatinib/Camrelizumab/Efficacy observation
